These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 19150421

  • 1. Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.
    Zikan V, Stepan JJ.
    Bone; 2009 Apr; 44(4):634-8. PubMed ID: 19150421
    [Abstract] [Full Text] [Related]

  • 2. Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate.
    Olmos JM, Hernández JL, Llorca J, Nan D, Valero C, González-Macías J.
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4491-7. PubMed ID: 23043189
    [Abstract] [Full Text] [Related]

  • 3. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.
    Cosman F, Nieves J, Woelfert L, Shen V, Lindsay R.
    J Bone Miner Res; 1998 Jun; 13(6):1051-5. PubMed ID: 9626638
    [Abstract] [Full Text] [Related]

  • 4. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 5. Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia.
    Dane C, Dane B, Cetin A, Erginbas M.
    Gynecol Endocrinol; 2008 Apr; 24(4):207-13. PubMed ID: 18382907
    [Abstract] [Full Text] [Related]

  • 6. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [Abstract] [Full Text] [Related]

  • 7. Consistency of bone turnover marker and calcium responses to parathyroid hormone (1-84) therapy in postmenopausal osteoporosis.
    Schafer AL, Palermo L, Bauer DC, Bilezikian JP, Sellmeyer DE, Black DM.
    J Clin Densitom; 2011 May; 14(1):68-73. PubMed ID: 21095149
    [Abstract] [Full Text] [Related]

  • 8. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B, San Martin J, Crans G, Pavo I.
    J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
    [Abstract] [Full Text] [Related]

  • 9. Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.
    Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis G, Kita M, Avramidis A.
    Horm Metab Res; 2008 Apr; 40(4):281-5. PubMed ID: 18275008
    [Abstract] [Full Text] [Related]

  • 10. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD.
    Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
    [Abstract] [Full Text] [Related]

  • 11. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
    Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W.
    Bone; 2007 May; 40(5):1238-43. PubMed ID: 17347063
    [Abstract] [Full Text] [Related]

  • 12. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate.
    Muñoz-Torres M, Reyes-García R, Mezquita-Raya P, Fernández-García D, Alonso G, Luna Jde D, Ruiz-Requena ME, Escobar-Jiménez F.
    Maturitas; 2009 Nov 20; 64(3):188-92. PubMed ID: 19819089
    [Abstract] [Full Text] [Related]

  • 13. [Effect of alendronate therapy on bone turnover--results of a multicenter study].
    Payer J, Killinger Z, Masaryk P, Tomková S, Kmecová Z, Ondrejková J, Necas L, Smoterová J, Ondrejka P, Kratochvilová H.
    Vnitr Lek; 2000 Oct 20; 46(10):689-92. PubMed ID: 11344627
    [Abstract] [Full Text] [Related]

  • 14. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy.
    Christgau S, Bitsch-Jensen O, Hanover Bjarnason N, Gamwell Henriksen E, Qvist P, Alexandersen P, Bang Henriksen D.
    Bone; 2000 May 20; 26(5):505-11. PubMed ID: 10773591
    [Abstract] [Full Text] [Related]

  • 15. Gender variation in PTH sensitivity and rhythmicity following growth hormone replacement in adult growth hormone-deficient patients.
    White HD, Ahmad AM, Syed AA, Clewes A, Peter R, Vora JP, Fraser WD.
    Clin Endocrinol (Oxf); 2004 Apr 20; 60(4):516-26. PubMed ID: 15049968
    [Abstract] [Full Text] [Related]

  • 16. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, Bianchi G.
    Nephrol Dial Transplant; 2009 May 20; 24(5):1472-7. PubMed ID: 19075192
    [Abstract] [Full Text] [Related]

  • 17. The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities.
    Hansdóttir H, Franzson L, Prestwood K, Sigurdsson G.
    J Am Geriatr Soc; 2004 May 20; 52(5):779-83. PubMed ID: 15086661
    [Abstract] [Full Text] [Related]

  • 18. Effects of short-term risedronate on bone resorption and patient satisfaction in postmenopausal osteoporosis patients.
    Fernandes CE, Zerbini C, Russo LA, Albernaz MA, Eis SR, Szejnfeld VL, Pompei LM.
    J Clin Densitom; 2009 May 20; 12(1):77-83. PubMed ID: 19004654
    [Abstract] [Full Text] [Related]

  • 19. Effect of raloxifene and clodronate on bone density in postmenopausal osteoporotic women.
    D'Amelio P, Muratore M, Tinelli F, Tamone C, Cosentino L, Quarta E, Calcagnile F, Carlo Isaia G.
    Int J Tissue React; 2003 May 20; 25(2):73-8. PubMed ID: 14518596
    [Abstract] [Full Text] [Related]

  • 20. Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial.
    Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis GN, Efstathiadou Z, Kita M, Avramidis A.
    Int J Clin Pract; 2008 Jun 20; 62(6):919-24. PubMed ID: 18422590
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.